Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

This study has been completed.

Study NCT00488592 Information provided by National Institutes of Health Clinical Center (CC)

First Received: June 19, 2007 Last Updated: May 14, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	April 2010
Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

No publications provided by National Institutes of Health Clinical Center (CC)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011 Mar;96(3):432-40. Epub 2010 Dec 6.